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observational impact study
Adrian Bamford1, Andy Nation1, Susie Durrell1, Lazaros Andronis2, Ellen Rule3 and Hugh McLeod2*
Abstract
Background: The Keele stratified care model for management of low back pain comprises use of the prognostic
STarT Back Screening Tool to allocate patients into one of three risk-defined categories leading to associated
risk-specific treatment pathways, such that high-risk patients receive enhanced treatment and more sessions
than medium- and low-risk patients. The Keele model is associated with economic benefits and is being widely
implemented. The objective was to assess the use of the stratified model following its introduction in an acute
hospital physiotherapy department setting in Gloucestershire, England.
Methods: Physiotherapists recorded data on 201 patients treated using the Keele model in two audits in 2013
and 2014. To assess whether implementation of the stratified model was associated with the anticipated range
of treatment sessions, regression analysis of the audit data was used to determine whether high- or medium-risk
patients received significantly more treatment sessions than low-risk patients. The analysis controlled for patient
characteristics, year, physiotherapists’ seniority and physiotherapist. To assess the physiotherapists’ views on the
usefulness of the stratified model, audit data on this were analysed using framework methods. To assess the potential
economic consequences of introducing the stratified care model in Gloucestershire, published economic evaluation
findings on back-related National Health Service (NHS) costs, quality-adjusted life years (QALYs) and societal productivity
losses were applied to audit data on the proportion of patients by risk classification and estimates of local incidence.
Results: When the Keele model was implemented, patients received significantly more treatment sessions as the risk-
rating increased, in line with the anticipated impact of targeted treatment pathways. Physiotherapists were largely
positive about using the model. The potential annual impact of rolling out the model across Gloucestershire is a gain in
approximately 30 QALYs, a reduction in productivity losses valued at £1.4 million and almost no change to NHS costs.
Conclusions: The Keele model was implemented and risk-specific treatment pathways successfully used for patients
presenting with low back pain. Applying published economic evidence to the Gloucestershire locality suggests that
substantial health and productivity outcomes would be associated with rollout of the Keele model while being
cost-neutral for the NHS.
Keywords: Low back pain, Stratified care model, STarT Back Screening Tool, IMPaCT Back, Implementation study,
Physiotherapy, Economic evaluation
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Background
Low back pain (LBP) has reached epidemic proportions,
affecting a large number of people each year and with a
lifetime prevalence of up to 80% [1, 2]. Each year in
England, about 2.3 million people, 4.2% of the popula-
tion, consult a general practitioner (GP) at least once
for LBP [3], and these individuals represent about 20%
of those with LBP [4]. Back pain causes considerable
discomfort and is a leading cause of work absence and
economic loss [1, 5]. UK costs associated with back pain
were conservatively estimated in 1998 prices as follows:
NHS treatment £1.1 billion, private treatment £0.6 billion,
informal care £1.6 billion, employment-related productiv-
ity loss costs £3.4 billion [1]. These figures underline the
impact of LBP on society.
A wide range of therapies have been used for treatment
of LBP [6], although clinicians’ views on appropriate ther-
apies have varied [7] along with reported uncertainty
about the value of treatment options [8] and calls for re-
search on cost-effectiveness [9]. The type of treatment for
which there is most economic evidence is combined phys-
ical and psychological interventions. These include those
that are physiotherapist-led (spanning the use of the Keele
stratified care model [10–13], group exercise and educa-
tion sessions [14], two pain-management programmes
[15, 16] and spinal stabilisation physiotherapy [16]), multi-
disciplinary (with input from different combinations of
physiotherapists, nurses, psychologists or professional
counsellors) [17–20], and a psychologist-led intervention
[21]. With one exception [15], the interventions have been
compared to usual care and found to be cost-effective.
However, the main evaluation perspectives taken in these
studies vary from healthcare system (such as the NHS) to
healthcare (system and private) to societal (healthcare and
productivity losses), and this makes it difficult for clini-
cians and local commissioners to compare treatment
options.
The Keele stratified care model
The Keele stratified care model for management of LBP
comprises use of the prognostic STarT Back Screening
Tool to allocate patients into one of three risk-defined
categories [22] followed by delivery of associated risk-
specific treatment pathways [10]. All patients receive a
30-min session with a physiotherapist comprising reassur-
ance, education, and treatment specific to the patient’s
screening tool score [23]. Low-risk patients receive no fur-
ther intervention. Medium-risk patients present with pre-
dominantly physical prognostic indicators and are referred
for further physiotherapy. The high-risk patients are also
referred for further physiotherapy which is designed to ad-
dress the high psychosocial indicators, such as anxiety and
fear, with which they present. A training package is re-
quired for the physiotherapists to enable them to deliver
the treatment pathways [23]. The intention of the strati-
fied care model was to change the pattern of treatment
such that it would better target appropriate interventions
and improve patient outcomes. The initial randomised
controlled trial (the STarT Back trial) comparing the
stratified care model to usual care was designed so that all
eligible LBP patients identified from routine general prac-
tice records were seen in a physiotherapy clinic [10]. This
does not reflect usual practice, where GPs are the first-
contact clinician and only a minority of LBP patients are
referred to physiotherapy [10]. The subsequent IMPaCT
Back study was a sequential comparison study designed to
explore the impact of the Keele stratified care model when
implemented by GPs [12, 13]. Both the STarT Back and
IMPaCT Back studies found that the stratified care
model’s treatment pathways change the pattern of usual
treatment resulting in an increase in the number of treat-
ment sessions provided as the risk-classification increases.
The IMPaCT Back study found that over a 6-month post-
implementation period (phase 3) the stratified care model
was associated with a gain in mean quality-adjusted
life years (QALYs) of 0.003 per patient compared to a
6-month pre-implementation period (phase 1) [12]. An in-
crease in mean back-related NHS costs over 6 months of
£1.75 per patient was associated with stratified care com-
pared to a reduction in mean costs of £33.54 when private
treatment costs were included [12, 13]. Stratified care was
also associated with a mean saving in indirect productivity
loss costs associated with LBP-related work absence of
£400 per employed patient over the 6-month period [12].
Aims
The Keele stratified care model has attracted considerable
NHS [24] and international [25] interest since the initial
randomised controlled trial findings were published in
2011 [10], but there is little published information on its
performance and usefulness in everyday practice [24, 25].
With this in mind, we set out to assess the impact of the
model following its implementation as a pilot by physio-
therapists at Gloucestershire Hospitals NHS Foundation
Trust (GHT), an acute hospital physiotherapy department
setting in Gloucestershire, England, in 2013. Use of the
stratified care model is assessed in terms of three criteria:
evidence of i) whether it was associated with the antici-
pated treatment pathways as represented by the number
of risk-specific treatment sessions provided, ii) the physio-
therapists’ views on the usefulness of the stratified care
model because the model is more likely to inform clinical
behaviour if it is viewed as useful by the physiotherapists,
and iii) the potential consequences for NHS and private
treatment costs, QALYs, and societal productivity losses
associated with the rollout of the stratified care model in
Gloucestershire.
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Methods
Design and setting
Treatment for LBP in Gloucestershire is provided by
physiotherapists in the outpatient departments of both
the local acute hospital and community care provider
Trusts. Referrals to both services are received either
from a GP or patient self-referral. The acute hospital
physiotherapy service introduced the Keele stratified care
model in Spring 2013, when patients presenting with LBP
at one of the two acute hospital sites started to complete
the prognostic STarT Back Screening Tool to determine
their risk-rating at the first physiotherapy appointment. In
order to audit this service innovation, an audit was under-
taken during 15 weeks from March 2013 and repeated
during 8 weeks from June 2014, by AN as part of the
Trust’s empowered leadership programme. The audit data
were essential for the study because diagnostic codes are
not routinely recorded on electronic systems for out-
patient attendances at the Trust and so in their absence it
would have been necessary to examine paper patient
physiotherapy records to identify patients.
The GHT audit data allow an observation cohort de-
sign for the study, which also draws on the findings of
the IMPaCT Back sequential comparison study to assess
two of the study’s aims: whether the introduction of the
stratified care model was associated with the anticipated
treatment pathways, and what the potential consequences
of rolling out the model in Gloucestershire would be for
NHS and private treatment costs, QALYs, and societal
productivity losses.
Data
In each audit, physiotherapists were requested to complete
an audit form on 100 consecutive patients for whom the
patients’ risk-rating had been determined. The sample size
was determined on pragmatic grounds to be logistically
feasible. The data recorded included: patient hospital
number, Keele STarT Back Screening Tool score (1 to 9),
risk-defined category (low, medium, high), clinical impres-
sion/differential diagnosis, number of treatment sessions,
type of treatment, outcome, ‘yes’ or ‘no’ response to the
question ‘In your opinion did the risk category accurately
reflect the patient?’, free text response to ‘Reflection - use-
fulness of the tool/did it guide patient management etc’.
The audit forms were logged on a summary sheet that in-
cluded a physiotherapist identifier code and the date on
which the patient was first seen by a physiotherapist. A
classification code for the physiotherapists’ seniority was
added to the dataset on the basis of the recorded physio-
therapist identifier code by the head of service (SD), to
distinguish physiotherapists up to grade 5 from those in
higher grades. Where possible, the patient hospital num-
ber and the initial attendance date were used to determine
the patient gender and age in years from the electronic
patient administration system. The 2013 audit data for a
small number of patients were recorded before the patient
was discharged and so, where possible, the patient hospital
number and the initial attendance date were used to de-
termine the number of physiotherapy sessions undertaken
from the patient administration system.
Analysis
Statistical analyses was used to assess whether implemen-
tation of the stratified care model was associated with the
anticipated treatment pathways as represented by the
number of risk-specific treatment sessions provided. This
involved i) generating descriptive statistics for the number
of treatment sessions provided and comparing them to
those for the STarT Back and IMPaCT Back studies, ii)
carrying out regression analysis using a multilevel linear
mixed-effects model to examine the relationship between
the patient-level number of treatment sessions and the
risk-defined category, controlling for patient age, gender,
year of audit, physiotherapists’ seniority and physiotherap-
ist. The risk-defined category was included as a fixed-
effect categorical variable, and the patient age in years was
included as a fixed-effect continuous variable. Gender
(1 = female, 2 = male), year of audit (1 = 2013, 2 = 2014),
and physiotherapists’ seniority (1 = up to grade 5, 2 =
higher grades) were included as fixed-effect dichotomous
variables. Physiotherapist was included as a random-effect
categorical variable in order to account for a possible
physiotherapist-level cluster effect. Log transformation of
the treatment session data was undertaken in order to re-
duce the right-skewness of the distribution due to the
small number of patients receiving a comparatively large
number of treatment sessions. The Kernel density esti-
mate of the treatment session square root transformation
was closer to normality compared to the Kernel of either
the square root transformation or the natural units. The
exponential of each fixed-effect coefficient is reported, as
it represents the expected percent change in the number
of treatment sessions associated with a one unit change in
the independent variable [26]. Statistical significance was
set at the 5% level. STATA version 12 software was used
for the analysis. In order to provide an alternative measure
of physiotherapist-level effects, a linear fixed-effects re-
gression model was also run. However, the results were
not sensitive to choice of model and so the results of the
linear fixed-effects regression model are not reported here.
Sensitivity analysis included omitting physiotherapist as
an independent variable. A small-scale data validation ex-
ercise was undertaken for six patients to check the extent
to which the physiotherapist’s record of the number of
physiotherapy sessions matched the medical records and
number of sessions recorded in the electronic patient
administration system. No evidence of discrepancies
was found.
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Audit data on whether the physiotherapist thought the
risk category accurately reflected the patient were analysed
to assess the percentage of patients and mean number of
treatments by risk group to see if there was a link between
valuing the tool and adopting a treatment strategy that
reflected the risk category it produced. To further explore
the physiotherapists’ views on the usefulness of the strati-
fied care model, the free text data on this question were
analysed using framework methods [27]. Framework uses
a thematic structure to summarise and classify case-based
data that are organised in a series of matrices. Text is
coded to represent key topics/themes and recorded in col-
umns, with rows representing individual informants. This
facilitates exploration of themes and patterns across the
range of informants. In this study, the physiotherapists’
views were first classified by whether the physiotherapist
viewed the risk-rating tool as accurately reflecting the pa-
tient. The physiotherapists’ comments were then coded as
‘useful’ or ‘not useful’ before associated attributes were
identified.
The potential consequences for NHS and private back-
related treatment costs, QALYs, and societal productivity
losses associated with the rollout of the stratified care
model in Gloucestershire were modelled by applying the
local audit data on the proportion of patients by risk
classification and estimates of local incidence to the pub-
lished 6-month parameter estimates from the IMPaCT
Back study [13]. Costs included consultations with GPs
and practice nurses, consultations with other healthcare
professionals, hospital-based procedures, prescribed medi-
cation, and out-of-pocket expenditures on treatments
and/or aids [13]. The impact on treatment costs is re-
ported from the perspectives of the NHS, private, and
healthcare (NHS and private). Productivity losses are re-
ported from a societal perspective. The impact of the
stratified care model can be expressed in terms of net
monetary benefit (NMB). The incremental benefit is
rescaled into monetary value using the cost-effectiveness
threshold to value each unit of benefit, and the incremen-
tal cost is subtracted from this value to give the NMB
[28]. The cost-effective threshold used by the National In-
stitute of Health and Care Excellence (NICE) is £30,000
per QALY, and this value is used in our analysis [28]. As a
sensitivity analysis we also apply a cost-effective threshold
of £15,500 per QALY which was empirically estimated for
musculoskeletal treatment by Claxton et al. [29] and re-
ported by Drummond et al. [28] table 4.3.
The proportions of patients by risk classification were
estimated from the GHT audit data. The annual number
of LBP patients referred from general practice for
physiotherapy treatment was estimated as 20% [12, 30]
of the consulting prevalence for LBP from an observa-
tional study of primary care consultations [3], applied to
Gloucestershire gender and age-specific population rates
from Office for National Statistics mid-year estimates for
2013 [31]. The estimate of 20% of the consulting preva-
lence was increased to 25% in a sensitivity analysis. The
2008/9 back-related costs from the IMPaCT Back study
[13] were translated into 2013/14 values using the hos-
pital and community health services (HCHS) index to
account for pay and price inflation [32]. A sensitivity ana-
lysis of the percentage of patients in each risk-category
was undertaken assuming the percentages from the
IMPaCT Back study in place of the GHTaudit findings.
Results
The GHT audits included 201 patients presenting with
LBP, of whom 59% (118/201) were female. Patient age
was recorded for 92% (184/201) of the patients and the
mean age was 51 years (range 16 to 90 years). The 201
patients were seen by 29 physiotherapists; 23 participated
in the 2013 audit, 18 in 2014, and 12 in both audits.
Patients were randomly allocated to a physiotherapist
and on average each participating physiotherapist saw
6.9 patients (range 1 to 36 patients).
Treatment pathways
After the introduction of the Keele model, 2.7 physio-
therapy sessions were provided to the LBP patients, on
average, and the trend was for more sessions to be pro-
vided on average as the risk-rating increased (Table 1).
Similarly, the trend was that more sessions were pro-
vided on average in 2014 compared to 2013.
The experience of the GHT audit patients was similar
to that of patients in the IMPaCT Back study, such that
the trend was for more sessions to be provided on aver-
age as the risk-rating increased (Table 2). This compari-
son is based on the 57% (314/554) of patients in the
IMPaCT Back phase 3 for whom data on resource use
was available (Table 2) [13]. Table 2 also illustrates the
impact of the introduction of the stratified care model in
the IMPaCT Back study, in terms of the increase in the
mean number of treatment sessions, particularly for pa-
tients in the medium- and high-risk categories.
Overall, 33% (66/201) of the patients in the GHT audits
were classified as high-risk, compared to 38% medium-
risk and 29% low-risk (Table 1). The GHT experience was
for a larger proportion of patients to be classified as high-
risk compared to the 20% (108/554) experienced in the
post-implementation phase of the IMPaCT Back study
(Table 2). The chi-squared test indicates that the propor-
tions in each risk category in the GHT audits compared to
the post-implementation phase of the IMPaCT Back study
were significantly different (p < 0.01) (Tables 1 and 2).
The multilevel linear mixed-effects model was used to
examine the relationship between the number of treat-
ment sessions and the risk-defined category, while con-
trolling for patient and physiotherapist-level variables
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(Table 3). The audit year, patient gender and physiother-
apists’ seniority were not significant explanatory vari-
ables (Table 3). However, compared to patients in the
low-risk category, patients in the medium- and high-risk
categories received on average 29.3% and 54.6% more
treatment sessions, respectively, and these differences
were statistically significant (Table 3). This finding con-
firms that GHT experienced treatment patterns, in
terms of the number of physiotherapy sessions provided,
in line with the expectations of the stratified care model.
Running the model with patient age for the 184 pa-
tients for whom the data were available did not change
the results. In order to provide an alternative measure of
physiotherapist-level effects, a linear fixed-effects regres-
sion model was also run. The risk-category results were
not sensitive to choice of model (patients in the
medium- and high-risk categories received on average
31.0% or 61.9% more treatment sessions, respectively,
compared to patients in the low-risk category, and these
differences were significant at the 5% level), although the
audit year variable was also significant and indicated that
patients in the 2014 audit received 24.7% more treat-
ment sessions than those in the 2013 audit. Omitting
physiotherapist as an independent variable altogether in
a fixed-effects model found patients in the high-risk
category receiving on average 55.3% more treatment
sessions, compared to patients in the low-risk category,
and the difference was significant (p = 0.01), but the
25.8% increase for medium-risk patients was not sig-
nificant (p = 0.06).
Physiotherapists’ views on the usefulness of the stratified
care model
The audits requested the physiotherapist to record their
view on whether or not the risk category accurately
reflected the patient, in other words whether they thought
that the prognostic risk-rating had aided them in man-
aging the condition, and any comment on the usefulness
of the screening tool. These data for the high-risk patients
in the 2013 audit were not available for the study and so
the analysis of these data is limited to the 2014 audit. In
67% (67/100) of cases the physiotherapist indicated that
the screening tool had accurately reflected the patient,
compared to 15% taking the opposite view, and 18% not
responding to the question (Table 4). When the physio-
therapist noted that the screening tool had accurately
reflected the patient, the pattern of mean treatment ses-
sions was in line with the expectations of the stratified
care model: more sessions were provided to higher-risk
patients (Table 4). However, this was not the case when
physiotherapist noted that the screening tool had not ac-
curately reflected the patient, or had not responded to the
question (Table 4).
In the 2014 audit, comments were recorded by 13 of
the 18 physiotherapists on their views of the usefulness
of the screening tool for 43 of the 100 patients, and
other comments were reported for a further 12 cases.
Our analysis of the comments focuses first on those
cases where the screening tool was viewed as having ac-
curately reflected the patient, before considering those
cases where the screening tool was not viewed as having
accurately reflected the patient. In the two-thirds of
cases when the physiotherapist had indicated that the
screening tool had accurately reflected the patient, the
comments on usefulness were positive in 93% (28/30)
cases. The positive comments applied across risk categor-
ies, patient ages, physiotherapist seniority, diagnoses and
treatments, and they suggest benefits for both the patient,
for example “prompted discussion about concerns –
enabling reassurance”, and physiotherapist, for example
“v useful, guided me to give advice & d/c [discharge]”.
For low-risk patients the feedback suggests that use of
the tool guided management and discharge, while for
medium- and high-risk patients it facilitated commu-
nication between physiotherapists and patients which
led to anxiety being identified and then addressed.
Table 3 GHT audits multilevel linear regression model coefficients for log of the number of treatment sessions
fixed effects coefficient exponential of coefficient p value 95% CIs
audit year 0.146 1.157 0.160 −0.058 to 0.350
patient gender 0.061 1.063 0.529 −0.130 to 0.253
physio seniority −0.132 0.876 0.351 −0.410 to 0.145
Risk (low)
medium 0.257 1.293 0.032 0.022 to 0.492
high 0.435 1.546 <0.001 0.192 to 0.679
intercept 0.389 1.475 0.184 −0.184 to 0.961
Random effects estimate 95% CIs
physiotherapist
sd cons 0.191 0.077 to 0.470
sd residual 0.667 0.601 to 0.741
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Two comments were not positive; one was for a low-
risk patient presenting with posterior/lateral derange-
ment who received five treatment sessions before being
discharged and the physiotherapist’s comment was
“Due to symptoms & progressions of HEP [home exercise
programme] needed low category did not reflect no. of
treatments needed. Also had hip issue which needed
clarification”. The other case was a medium-risk pa-
tient presenting with mechanical LBP who received one
treatment session before being discharged and the
physiotherapist’s comment was “No it didn’t guide
management”.
Comments on usefulness were made for 13 of the 15
cases where the physiotherapist had indicated that the
screening tool had not accurately reflected the patient.
In the four low-risk cases, the physiotherapist viewed
the patient as being more anxious or requiring more
clinical support than that indicated by the low-risk clas-
sification, and in each case the patient received more
than one treatment session. Of the six medium-risk
cases, comments on two indicated that the risk-rating
may not be optimal; being either too high “More easily
reassured than tool score suggested” or too low “I feel
high risk category may have been more appropriate”. In
two cases, the comments indicated that the use of any
care model was not relevant; “Did not guide treatment
as pt v specific about what she wanted” and “Not useful
as pt seeking advice about falls protection”. In the other
two cases, the comments do not provide insight into
why the screening tool was “not helpful” or “not relevant
for this pt”. Of the high-risk patients, two cases suggest
that initial patient anxiety was addressed such that the
high-risk classification may not have been warranted:
“Anxious due to acute onset but able to reassure” was
the comment for one of patients, who did not attend a
second treatment session. The third high-risk case ap-
peared to illustrate inappropriate completion of the
screening tool: “Main problem OA hip & pt misinter-
preted tool by answering re hip pain”. Overall, where the
physiotherapist had indicated that the screening tool had
not accurately reflected the patient, their comments sug-
gest the risk-rating was viewed as too low in five cases
and too high in three cases.
Potential economic consequences associated with the
rollout in Gloucestershire
The IMPaCT Back study estimated the incremental
change in NHS costs and healthcare costs (NHS and pri-
vate) associated with the introduction of the stratified
care model using data imputation methods for its full
patient sample (n = 922) (Table 5) [12]. The changes in
these costs by risk category up-rated to 2014/15 values
are summarised in Table 5, which shows that applying
the percentage of patients in each risk-category
experienced in the GHT audits (Table 1), generates an
estimated aggregate incremental back-related NHS cost
saving of £0.65 per patient associated with the stratified
care model. Similarly, applying the IMPaCT Back study’s
estimated incremental change in QALYs to the percent-
ages of patients in each risk-category experienced in the
GHT audits gives an estimated aggregate incremental
QALY gain of 0.006 per patient associated with the
stratified care model (Table 5). The estimated annual
number of patients referred for LBP physiotherapy treat-
ment in Gloucestershire is 5217 patients (Table 5),
which suggests a NHS cost saving of approximately
£3400 per annum and an associated gain of approxi-
mately 30.2 QALYs and a net monetary benefit of ap-
proximately £909,000. The NMB is based on the cost-
effectiveness threshold associated with NICE of £30,000
per QALY, and an alternative empirically estimated
threshold of £15,500 per QALY for musculoskeletal
treatments implies associated NMB of £471,000.
The estimate of the annual number of patients re-
ferred for LBP physiotherapy treatment may be conser-
vative; it assumes that 20% of the estimated annual
consulting prevalence for LBP in primary care is re-
ferred. In practice, for example, some LBP patients may
be referred for physiotherapy more than once in a year.
If 25% of the estimated annual consulting prevalence for
LBP in primary care is referred, the annual NHS cost
saving would be approximately £4200 with an associated
gain of 37.7 QALYs and NMB of £1,136,000 (or
£589,000 based on the alternative empirically estimated
cost-effectiveness threshold).
These findings are sensitive to the percentage of pa-
tients in each risk-category; applying those for all pa-
tients in the post-implementation phase of IMPaCT
Back study (Table 2) result in an overall increase in
mean back-related NHS costs of £1.13 per patient
(£1.03 up-rated to 2014/15 values). This indicates an
increase in NHS costs of approximately £5900 and an
increase in 14.1 QALYs and NMB of £418,000 (or
£213,000 based on the empirically estimated threshold)
in Gloucestershire.
The IMPaCT Back study reported productivity losses
associated with LBP-related work absence following the
introduction of the stratified care model [13], which sug-
gests a mean saving of £545 per employed patient (in
2014 values) (Table 6). Applying the IMPaCT study’s es-
timates of the percentage of LBP patients in work, and
the mean change in the number of days of LBP-related
work absence during the 6 months following the intro-
duction of the stratified care model, to the estimated
annual number of patients referred for LBP physiother-
apy treatment in Gloucestershire, suggests a saving of
approximately 10,500 days of work absence valued at
£1.4 million (Table 6).
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As above, assuming a higher estimate of incidence of
25% of the annual consulting prevalence indicates a
productivity loss saving of approximately 13,100 days of
work absence valued at £1.8 million. Alternatively apply-
ing the percentage of patients in each risk-category from
the IMPaCT Back study post-implementation phase
(Table 2) result in a mean saving of £461 per employed
patient (in 2014 values), and an aggregate productivity
loss saving of approximately 9000 days of work absence
valued at £1.2 million.
Discussion
In 2013, the physiotherapy department at GHT started
to use the stratified care model for LBP patients, with
the expectation that prognostic screening and matched
treatment pathways would improve the pattern of activ-
ity, such that at the extremes low-risk patients would be
appropriately discharged after a single treatment session,
and high-risk patients would receive a psychologically-
informed treatment package to address psychosocial ob-
stacles to recovery as well as physical symptoms and
function [10]. The analysis of the GHTaudit data indicates
that the use of the stratified care model was broadly asso-
ciated with the anticipated pattern of treatment sessions.
On the whole, patients received more treatment sessions
as the patients’ risk-rating increased, having controlled for
patient and physiotherapist characteristics, which suggests
that the stratified care model was supporting the intended
treatment practice.
The physiotherapists’ audit feedback on the model
confirmed that the risk-rating was viewed as accurately
reflecting the patient in 82% (67/82) of the cases where
data were reported. Comments on the cases where the
patient was not viewed as being accurately reflected by
the risk-rating indicated a few cases where the physio-
therapist felt that a different rating would have been ap-
propriate. One of the factors cited relates to patient
anxiety, and to the extent that its impact can be ad-
dressed, the findings suggest that it is important for
physiotherapists to have appropriate specialist training.
When the physiotherapists viewed the prognostic risk-
rating as having aided them in managing the LBP, the
mean number of treatment sessions was 1.6, which indi-
cates that many of these low-risk patients were dis-
charged after one session in line with expectations of the
Keele model. The audit data also show that there were a
few instances where the model was not viewed as rele-
vant because, for one reason or another, the patient was
not primarily seeking treatment for LBP. This issue may
have influenced the omission of recording a response to
the audit question on whether or not the tool accurately
reflected the patient. If we assume that all non-responses
to this question indicated that the risk-rating was not
viewed as accurately reflecting the patient, then in 67%
(67/100) of the cases the audit feedback on the model
confirmed that the risk-rating was viewed as accurately
reflecting the patient. When the physiotherapists’ gave
feedback on the prognostic screening tool it was domi-
nated by positive views, which represent an important
component of this impact assessment.
The potential economic consequences associated with
the introduction of the stratified model in Gloucester-
shire were estimated by applying published economic
evaluation findings on back-related NHS costs, QALYs
and societal productivity losses to the local experience of
the proportion of patients in each risk category, and es-
timates of local incidence. This approach suggests that
the introduction of the model could achieve an annual
incremental gain of about 30 QALYs generating a net
monetary benefit of £471,000, on the basis of an empir-
ically-estimated cost-effectiveness threshold of half the
level indicated by NICE. Looking beyond benefits associ-
ated with health-related quality of life, the economic
evaluation evidence suggests that a societal benefit from
fewer work days lost because of LBP corresponds to a
productivity loss saving of £1.4 million which could be
achieved by rolling out the model in Gloucestershire. The
economic evaluation evidence suggests that these benefits
are associated with almost no impact on NHS costs.
The strengths of the study lie in its analysis combining
local audit data and published economic evaluation re-
sults to assess the potential of the stratified care model
in a physiotherapy department setting. The analysis of
the physiotherapists’ views of the risk-rating is a strength
of the study, albeit limited by the necessity to focus on
the 2014 audit data. The analysis demonstrates a prag-
matic approach to applying trial findings to a real world
scenario. The analysis is limited by its reliance on the
audits to collect data on use of the stratified care model,
and literature-based estimates of the number of LBP pa-
tients receiving physiotherapy. While our findings may
not be generalisable to other settings, our analytical ap-
proach could be widely employed to assess the potential
impact of the stratified care model.
The extent to which the IMPaCT Back study can in-
form the potential impact of introducing the stratified
care model in a setting such as Gloucestershire depends
on the extent to which the study’s experience is likely to
be relevant. The general context is similar in terms of
both settings being in the NHS in England, and the
IMPaCT Back study being based on largely urban general
practices in Staffordshire, while the Gloucestershire audits
were based on patients mostly from the Gloucester lo-
cality. However, the IMPaCT Back study involved GPs
administering the screening tool and hence their decisions
to refer patients for physiotherapy, whereas in Gloucester-
shire the tool was administered by physiotherapists fol-
lowing GP referral, or in some cases, patient self-referral.
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This means that the denominator in each setting is differ-
ent; the GHT patients represent a subset of comparatively
higher-risk referred patients, compared to those in the
IMPaCT Back study. This difference in context may
account for the 39% low-risk patients in the phase 3
IMPaCT Back study compared to 29% in the GHT au-
dits. The consequences are appreciable; the GHT risk-
specific percentages are associated with an additional
net monetary benefit of £201,000 compared to the phase 3
IMPaCT Back study, based on the conservative empirically-
estimated cost-effectiveness threshold. To the extent that
the stratified care model may for logistical reasons be more
likely to be implemented by physiotherapists for referred pa-
tients, rather than by GPs in primary care, the GHT experi-
ence provides new insight into the scale of the stratified care
model’s potential benefits. Having noted the similarities and
differences in context between the IMPaCT Back study and
the use of the tool in Gloucestershire, we view that the risk-
level treatment effects found in the IMPaCT Back study
provide a reasonable, and certainly the best available, basis
for estimating the potential consequences for rolling out the
stratified care model in Gloucestershire. The IMPaCT Back
study found that pre-implementation of the Keele model,
the mean number of treatment sessions increased with the
risk rating, and that after the introduction of the Keele
model, patients with higher risk-ratings received compara-
tively more treatment sessions. We assume that GHT will
experience similar risk-level treatment effects. Better esti-
mates of impact would require a local cost-utility analysis,
entailing collection of data on resource use, costs and
health-related quality of life, both before and after the intro-
duction of the Keele model and for a suitable control group.
Being a sequential comparison study, rather than a
randomised trial, the IMPaCT Back study must be con-
sidered with caution. Nevertheless, its findings about
the risk-specific incremental impact on NHS costs and
outcomes offer a guide for likely experience in Glouces-
tershire. From a commissioner’s decision-making per-
spective, the IMPaCT Back study’s main analysis would
have been even more informative if it had been under-
taken from an NHS perspective, in line with NICE
guidance [33], rather than a healthcare perspective. The
reported healthcare cost savings are due to a reduction
in mean private treatment costs largely experienced by
high-risk patients (Table 5). The inclusion of private
costs in the main Keele economic evaluations mean
that the analysis of uncertainty, using cost-utility planes
and cost-effectiveness acceptability curves, may be of
comparatively limited value for commissioners. Fur-
thermore, while the IMPaCT Back study’s reporting at
risk-defined subgroup level emphasises the dominance
of the intervention for high-risk patients, and the op-
posite for medium-risk patients, our analysis indicates
that the stratified care model is dominant for the whole
patient group represented by the GHT audits (i.e. reduced
NHS costs, albeit very slightly, and gains in health-related
quality of life). Economic theory indicates that the uncer-
tainty relating to this outcome, where differences in cost
and QALYs are not statistically significant [13] should not
impede implementation, but should prompt consideration
of commissioning a value of information study to assess
whether further research should be undertaken [34]. In
this instance, a pragmatic response would be to focus fu-
ture local quality improvement effort on ensuring that the
treatment package for medium-risk patients has an opti-
mal impact on health-related quality of life. This would be
facilitated by routine coding of outpatient attendances by
clinical diagnosis and, when used, the risk-stratification
scores.
The estimated net monetary benefit associated with
the adoption of the stratified care model is substantial,
despite the estimated mean incremental QALY gain be-
ing modest over 6 months (0.006), because of the large
number of patients and small cost consequences (Table 5).
This raises the question of whether other LBP interven-
tions are associated with larger impact on health-related
quality of life. The NHS advice, assessment and group
cognitive behavioural therapy (CBT) intervention reported
by Lamb et al. [19, 35, 36] stands out for achieving a com-
paratively large incremental QALY gain of 0.099 over
12 months. However, comparison with the stratified care
model is not straightforward. First, a follow-up study of
56% (395/701) of the original trial participants, who were
older and had less disability and pain at baseline compared
to the full patient cohort, found no incremental gain in
EQ5D scores at 3, 6, 12 or the average follow-up period of
34 months [36]. This suggests that as for the stratified care
model, QALY gains may be mostly attributable to those
patients with a poorer prognosis. Second, the CBT study
reported a secondary analysis of costs, aiming to reflect
the likely costs for NHS rather than those associated with
the delivery of the trial, which estimated a £96 incremental
NHS cost over 12 months largely due to the £126 inter-
vention cost per patient [35]. These costs represent a con-
siderable additional resource requirement in comparison
to the stratified care model of about £497,000 in Glouces-
tershire. Commissioners may favour the stratified care
model in this case because of the NHS resource conse-
quences. However, the CBT intervention’s estimated costs
may not be readily comparable with those of other non-
group-based interventions. This is because it allocated ses-
sion costs to the number of patients that attended, so the
cost of resource allocated to the patients who did not at-
tend sessions were included. In contrast, the cost of re-
source allocated to the patients who did not attend
booked physiotherapy sessions in the stratified care model
studies were not included. Furthermore, it may be that the
CBT intervention could be targeted and delivered in fewer
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sessions, as only 62% of participants attended at least 3 of
the 6 group sessions held [35]. Overall, it would be in-
teresting to see whether the stratified care model’s im-
pact on health-related quality of life could be enhanced
by combining the risk-stratification tool with targeted
use of group CBT. The draft guideline on the management
of non-specific LBP published by the National Clinical
Guideline Centre in February 2016 endorsed consideration
of the STarT Back risk assessment tool for risk stratifica-
tion along with a range of potential treatment options in-
cluding psychological therapies for managing LBP as part
of multi-modal treatment packages or combined physical
and psychological programme for people with persistent
LBP [37].
Conclusion
The Keele stratified care model was implemented and risk-
specific treatment pathways successfully used for patients
presenting with LBP for physiotherapy in Gloucestershire.
The physiotherapists’ feedback on using the prognostic
screening tool was very positive. Applying published eco-
nomic evidence to the Gloucestershire locality suggests
that substantial health and productivity outcomes would
be associated with rollout of the Keele model while being
largely cost-neutral for the NHS.
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